{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013246","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.757324+00:00","generated_at":"2026-05-30T15:13:34.066761+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A","bullets":["Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.","Initiated development of BP1001-A for obesity using DNAbilize technology; IND-enabling testing expected to begin in Q4 2024.","Completed enrollment of third dosing cohort (60 mg/m2) of Phase 1/1b trial of BP1002 in refractory/relapsed AML patients.","Cancelled prior June 2024 series A and B warrants (1,809,955 shares each) held by the same investor upon closing of this placement."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013246","json":"https://secwatch.observer/filing/0001558370-24-013246.json","markdown":"https://secwatch.observer/filing/0001558370-24-013246.md","text":"https://secwatch.observer/filing/0001558370-24-013246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/0001558370-24-013246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024013246/bpth-20241008x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T15:13:34.066761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}